Johnson & Johnson: Alzheimer Disease trials

The registry lists 54 Alzheimer Disease studies with Johnson & Johnson as lead sponsor. 1 are open to participants now and 9 have results posted.

Early Phase 1 3Phase 1 6Phase 2 8Phase 3 25Phase 4 5No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's DiseaseRecruitingNCT06540833Phase 2
• A Study of Seltorexant in Participants With Probable Alzheimer's DiseaseCompletedNCT05307692Phase 2Results posted
• ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's DiseaseTerminatedNCT02817906Phase 3Results posted
• An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's DementiaTerminatedNCT02569398Phase 2/3Results posted
• An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease SpectrumTerminatedNCT02406027Phase 2Results posted
• A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's DiseaseCompletedNCT01734395Results posted
• The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's DiseaseTerminatedNCT01181921Phase 4Results posted
• The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's DiseaseCompletedNCT01054976Phase 4Results posted
• An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's DiseaseCompletedNCT00814801Phase 3Results posted
• A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's DiseaseTerminatedNCT00679627Phase 3Results posted
• A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's DiseaseActive, not recruitingNCT06544616Phase 2
• A Study of JNJ-63733657 in Participants With Early Alzheimer's DiseaseTerminatedNCT04619420Phase 2
• A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha TherapyCompletedNCT04571697
• Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat)CompletedNCT03587376Early Phase 1
• A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's DiseaseCompletedNCT03375697Phase 1
• Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy ParticipantsCompletedNCT03239561Early Phase 1
• A Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human BrainCompletedNCT03089918Phase 1
• Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer DementiaCompletedNCT02360657Phase 1
• A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's DiseaseCompletedNCT02260674Phase 2
• Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research: Prospective Readiness Cohort StudyCompletedNCT02114372
• Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With DementiaCompletedNCT02078310Phase 1/2
• A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's DiseaseCompletedNCT01978548Phase 1
• Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From DonepezilCompletedNCT01478633Phase 4
• A Study to Evaluate Sleep Quality in Patients With Mild to Moderate Alzheimer's DiseaseCompletedNCT01478204
• A Study to Measure CSF Proteins in Elderly Healthy Volunteers and Volunteers With Mild Cognitive Impairment or Alzheimer's DiseaseCompletedNCT01436188Early Phase 1
• The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic PatientsTerminatedNCT01137799Phase 1
• Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily RoutineCompletedNCT01009476
• A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's DiseaseCompletedNCT00645190Phase 3
• Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's DiseaseCompletedNCT00338117Phase 3
• A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.CompletedNCT00309725Phase 3
• Long-term Safety and Efficacy of Galantamine in Alzheimer's DiseaseCompletedNCT00304629Phase 3
• An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.CompletedNCT00301574Phase 3
• An Observational Study of the Safety and Effectiveness of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month PeriodCompletedNCT00299676
• A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's DiseaseCompletedNCT00297362
• A Survey Study of the Treatment and Outcome Management in Patients Diagnosed With Alzheimer's DiseaseCompletedNCT00291421
• A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's DiseaseTerminatedNCT00287742Phase 3
• Use of Different Treatment Care Methods in Patients With Dementia Associated With Alzheimer's DiseaseCompletedNCT00283725
• A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed DementiaCompletedNCT00261573Phase 3
• A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's DiseaseCompletedNCT00253227Phase 3
• Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release FormulationCompletedNCT00253214Phase 3
• A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's DiseaseCompletedNCT00253201Phase 3
• A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's DiseaseCompletedNCT00253188Phase 3
• A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With DementiaCompletedNCT00253123Phase 3
• A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With DementiaCompletedNCT00249158Phase 3
• A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With DementiaCompletedNCT00249145Phase 3
• A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive ImpairmentCompletedNCT00236574Phase 3
• A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive ImpairmentCompletedNCT00236431Phase 3
• Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled StudyCompletedNCT00216593Phase 3
• The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer TypeCompletedNCT00216515Phase 4
• A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's DiseaseCompletedNCT00216502Phase 3
• Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's DiseaseCompletedNCT00082602Phase 3
• A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's DiseaseCompletedNCT00035204Phase 4
• Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's DiseaseCompletedNCT00034762Phase 3
• Evaluation of Galantamine in the Treatment of Alzheimer's DiseaseCompletedNCT00000172Phase 3